After the deal was initially signed in May, Samsung delivered an initial supply of active pharmaceutical ingredients (APIs) meeting good manufacturing practice (GMP) and regulatory expectations within five months, the firm said. What's more, technology transfer was completed in less than three months, according to Samsung.

The agreement supplements Lilly's internal manufacturing capacity.

FDA issues IND application to Dicerna, Lilly for RNAi candidate
Dicerna Pharmaceuticals' investigational new drug (IND) application for LY3561774, an RNA interference (RNAi) therapeutic, has been accepted by the U.S....

Seed Therapeutics, Eli Lilly to develop 'molecular glue' therapeutics
Seed Therapeutics has entered into a research collaboration and license agreement with Eli Lilly to discover and develop new chemical entities that could...

FDA grants Lilly EUA for its COVID-19 mAb
The U.S. Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for Eli Lilly's investigational monoclonal antibody (mAb) therapy,...

Samsung Biologics partners on antibody development, manufacturing
Samsung Biologics has announced that its contract development and manufacturing organization services have been selected by two companies for their antibody...

Samsung Biologics, BioEleven partner on cancer immunotherapy
Samsung Biologics has entered into a strategic partnership with BioEleven to develop and manufacture BN-101A, a third-generation immunotherapy to treat...

Samsung Biologics, Kanaph Therapeutics partner on retinal disease therapy
Samsung Biologics and Kanaph Therapeutics are partnering on the development of KNP-301, a bispecific Fc fusion protein to treat retinal diseases.